Plain-English translation of NCT06595290 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a structured approach to treating hospitalized acute heart failure using four medications together: a RAS inhibitor (ACE inhibitor, ARB, or ARNI), a beta-blocker, an MRA, and an SGLT2 inhibitor. The study will compare patients who receive this coordinated medication strategy—starting in the hospital and increasing doses quickly over six weeks—with those who receive standard heart failure care.
Many heart failure patients don't receive optimal doses of proven life-saving medications, which may lead to more hospitalizations and worse outcomes. This trial is testing whether a rapid, structured approach to starting and increasing these four medications can help more patients survive and avoid returning to the hospital.
You likely qualify if…
You likely don't qualify if…
If you enter this trial, you will be randomly assigned to either standard care or the intensive medication protocol. If assigned to the intensive group, you will start all four medications before leaving the hospital and return for four visits over six weeks, where nurses and doctors will check your blood pressure, heart rate, and blood tests to ensure the medications are safe and working. All participants will have follow-up visits at 90 days and 180 days after joining the trial to see how well they are doing.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Vietnam